Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Should You Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $16.81, but opened at $16.05. Daiichi Sankyo shares last traded at $16.62, with a volume of 255,082 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Daiichi Sankyo has a consensus rating of “Buy”.

Daiichi Sankyo Stock Down 0.7%

The company has a market capitalization of $31.79 billion, a price-to-earnings ratio of 17.85, a P/E/G ratio of 1.20 and a beta of -0.25. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average price of $17.40 and a two-hundred day moving average price of $19.58.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a return on equity of 15.74% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, sell-side analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.91 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.